NCT00418002已完成1 期
A Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Single Dose Study in Non-Smoking Healthy Elderly Subjects Interleaved With a 2-Week Multiple Once Daily Dose Study to Explore Safety, Tolerability, Pharmacokinetics and Cognitive Effects After Oral Administration of AQW051
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Safety and tolerability.
研究概览
简要总结
The purpose of this study is to assess safety and tolerability of AQW051 administered in single and multiple doses to elderly healthy volunteers. In addition, pharmacokinetic effects will be assessed and the possible effects on cognition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 60 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and postmenopausal female subjects between 60 to 80 years of age and in good health as determined by past medical history.
- •Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion.
- •Male subjects must be using a double-barrier local contraception.
- •Body mass index must be within the range of 18 to
- •Subjects must weigh at least 50 kg to participate in this study.
- •The regular intake of concomitant drugs including thyroxine, paracetamol, low dose non-steroidal anti-inflammatory drugs, lipid lowering drugs, vitamins and dietary supplements without caffeine and nicotinic acid, and hormone replacement therapy is allowed, if on stable treatment for at least 3 months. Intake of nutritional supplements (e.g. omega-3, vitamins, minerals, cod-liver oil) is allowed.
- •Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent.
排除标准
- •Smokers (use of tobacco products in the previous 3 months).
- •Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (e.g. herbal supplements) within 2 weeks prior to study start except noted previously
- •Use of any central nervous system active drug and anticholinergic drugs during the previous 3 months and use of any drug or treatment known to cause major organ system toxicity during the previous 3 months is prohibited.
- •A past personal or close family medical history of clinically significant cardiac abnormalities.
- •Current diagnosis of cardiac arrhythmia derived from ECG and/or Holter ECG.
- •Current diagnosis of cardiovascular disease.
- •Current diagnosis or history of autonomic dysfunction (e.g. history of fainting, orthostatic hypotension, sinus arrhythmia).
- •History of Acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease) Clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis) Known hypersensitivity or severe adverse event to darifenacin or similar drugs Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize participation in the study Immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. Drug or alcohol abuse within the 12 months prior to dosing.
- •Diagnosis of cognitive impairment (Mini Mental State Exam < 27).
- •History or current diagnosis of a cerebrovascular disease (e.g., stroke, transient ischemic attacks, aneurysms).
- •Current DSM-IV diagnosis of major depression and/or any other DSM-IV Axis 1 diagnosis that may interfere with the evaluation of the patient's response to study medication, including other primary neurodegenerative dementia, schizophrenia, or bipolar disorder.
- •History or current diagnosis of an active, uncontrolled seizure disorder.
- •History of head injury or any other neurological disorder.
结局指标
主要结局
Safety and tolerability.
次要结局
- Pharmacokinetics at the end of the study.
- Effect of AQW051 on cognition as assessed by a computerized cognitive test battery.
- To assess a potential food effect on pharmacokinetics of AQW051.
- To explore the drug abuse liability potential of AQW051.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male SubjectsHealthyNCT00409500Novartis54
已完成
2 期
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseDyskinesiasDrug-inducedNCT01474421Novartis Pharmaceuticals71
已完成
1 期
A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy ParticipantsAPOL1-mediated Kidney DiseaseNCT05324410Vertex Pharmaceuticals Incorporated88
终止
1 期
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)Nonalcoholic SteatohepatitisNASHNCT04565717Alnylam Pharmaceuticals6
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy SubjectsHealthy VolunteersPharmacokinetics of ASP015KNCT02141425Astellas Pharma Global Development, Inc.16